Table 2.

Key safety information from IDegLira Phase 3a trials [12,54 ].

	DUAL I [12]			DUAL II [53]
	IDegLira	IDeg	Liraglutide	IDegLira	IDeg
	(n = 825)	(n = 412)	(n = 412)	(n = 199)	(n = 199)
Adverse events, n (%)	521 (63)	248 (60)	299 (73)	115 (57.8)	122 (61.3)
Serious adverse events, n (%)	19 (2)	8 (2)	14 (3)	7 (3.5)	11 (5.5)
Nausea, n (%)	73 (9)	15 (4)	81 (20)	13 (6.5)	7 (3.5)

Based on the safety analysis sets.

IDegLira: Insulin degludec/liraglutide; N: Number of subjects; %: Percentages of subjects.